Search results
Results from the WOW.Com Content Network
Tongue depressor. A tongue depressor or spatula is a tool used in medical practice to depress the tongue to allow for examination of the mouth and throat. Hobbyists, artists, teachers and confectionery makers use tongue depressors, which may also be referred to as craft sticks or popsicle sticks.
BrainPort is a technology whereby sensory information can be sent to one's brain through an electrode array which sits atop the tongue. [1] It was initially developed by Paul Bach-y-Rita as an aid to people's sense of balance, particularly of stroke victims. Bach-y-Rita founded Wicab in 1998. [2] [3] [4]
The MDA established a risk-based framework for the classification of medical devices and a regulatory pathway for medical devices to get to the market, created a regulatory pathway for medical device clinical trials, and established several post-market requirements including manufacturer registration and device listing with the FDA, good ...
It covers research on all aspects of cancer and cancer-related biomedical sciences and was established in 1941. The editor-in-chief is Chi Van Dang. [1] The journal was established in 1916 as the Journal of Cancer Research, was renamed American Journal of Cancer in 1931, and obtained its current name in 1941.
An existing cancer drug has shown promise in halting Parkinson's disease progression in mouse models. More research is needed to confirm these findings. Could an FDA-approved cancer drug help stop ...
The therapy, which uses a device, slowed the spread of cancer in the brain to 21.9 months, along with supportive care, compared to 11.3 months for supportive care alone in patients with non-small ...
Clinical Cancer Research is a peer-reviewed medical journal on oncology, including the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer, medical and hematological oncology, radiation therapy, pediatric oncology, pathology, surgical oncology, and clinical genetics.
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small cell lung ...